Trovagene Reports Ongoing Phase 1b/2 Trial For Onvansertib In Combo With FOLFIRI, Avastin Enrolled 12 Patients With 88% Response In 7 Of 8 Evaluable Patients, To-Date 3 Patients With Partial Response, 4 Patients With Stable Disease